{blacktriangledown}Natalizumab for multiple sclerosis?

doi:10.1136/dtb.2008.09.0021

Drug and Therapeutics Bulletin 2008;46:69-72; doi:10.1136/dtb.2008.09.0021

${blacktriangledown}$ Natalizumab for multiple sclerosis?

Relevant BNF section: 8.2.4

Around 2.5 million people worldwide have multiple sclerosis,of whom about 85,000 are in the UK.¹ ${blacktriangledown}$ Natalizumab (pronouncedna-ta-liz-you-mab; Tysabri – Biogen Idec), the first ina new class known as selective adhesion-molecule inhibitors,is licensed in the UK as monotherapy for "highly active" relapsing/remittingmultiple sclerosis.² Here we review natalizumab and assess itsplace for patients with multiple sclerosis.